Cellular Biomedicine Group (18629CBMG) - A transpacific cell therapy company

09:08 EDT 2 May 2017 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - Cellular Biomedicine Group: Cellular Biomedicine Group (CBMG) has seven preclinical CAR-T programs and two Phase I clinical trials using its CD19 CAR-T therapy in China, making it the only US-traded CAR-T company in this market. It has rights to the Dendristim lung cancer vaccine. In addition, it is adapting its osteoarthritis (OA) treatment ReJoin as an allogeneic product, AlloJoin, which will be developed in the US after an IND in 2017 or 2018.
ISIN: US15117P1021

Original Article: Cellular Biomedicine Group (18629CBMG) - A transpacific cell therapy company


More From BioPortfolio on "Cellular Biomedicine Group (18629CBMG) - A transpacific cell therapy company"

Quick Search

Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...